Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @OncLearnNetwork
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @OncLearnNetwork
-
Prikvačeni tweetHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
For
#WorldCancerDay
, we're offering $50 off the price of registration to select OLN live conferences: @GreatDebatesGI,@GreatDebatesHem,@ThoracicOnc and@LLMCongress. Register by Wednesday Feb. 5 using code WORLDCANCER at checkout: https://buff.ly/2vEsE38 pic.twitter.com/7Q4moKXgqw
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Dr Iyengar,
@UTSWNews, discusses the pros and cons of using proton therapy in the management of patients with stage III#NSCLC in this short video from the 2019@ThoracicOnc meeting.#lcsm Watch: https://buff.ly/2GRSoeJ pic.twitter.com/7e9xjlxFlk
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Findings from a meta-analysis of patients with bone metastases from
#CRPC treated with bone-targeted radioisotopes (RIs) suggest there may be survival benefits with α- versus β-emitting RIs.#prostatecancer More: https://buff.ly/36L0lgz pic.twitter.com/11PuoFFUWR
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Today is the final day to take advantage of early registration discounts for
#GDUHem2020 LA! Save $50 by registering tonight before midnight EST: https://buff.ly/36kAvAW@jmikhaelmd@JohnPLeonardMD@jaltmanmd@GreatDebatesHempic.twitter.com/izCgZFHeTk
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Oncology Learning Network proslijedio/la je Tweet
Today is the final day to take advantage of early registration discounts for
#GDUHem2020 LA! Save $50 by registering tonight before midnight EST: http://bit.ly/2QZDEAq@jmikhaelmd@JohnPLeonardMD@jaltmanmdHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Recurrence scores may help predict locoregional recurrence that could aid in treatment decision-making for postmenopausal patients with breast cancer.
#bcsm#breastcancer Full story: https://buff.ly/2S533bk pic.twitter.com/Pyoo90r50s
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Oncology Learning Network proslijedio/la je Tweet
Among patients in a multi-center study with colorectal cancer (CRC) with ypStage II and III disease after presurgery chemoradiotherapy (CRT), adjuvant oxaliplatin, leucovorin, and fluorouracil bolus (FOLFOX) improved disease-free survival: http://bit.ly/34eqpiB pic.twitter.com/EgeJqaizWr
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
In this podcast,
@mjmauroMD,@sloan_kettering, discusses results from a phase 1 trial which evaluated asciminib, an ABL1 kinase inhibitor, in patients with heavily pretreated#CML.#leusm#cmlsm Listen here: https://www.oncnet.com/podcasts/novel-abl1-kinase-inhibitor-active-heavily-pretreated-cml …pic.twitter.com/zBVlUbrzAv
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Oncology Learning Network proslijedio/la je Tweet
Early rates for
#GDUGI2020 NYC are in effect for just 4 more weeks. Don't forget: We have new, lower prices in 2020 for nurses, students, residents & fellows: http://bit.ly/34km5P4 pic.twitter.com/GTxrpVl2aS
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
To better understand the characteristics of relapse in
#ALL, Benshang Li, MD, et al carried out whole-genome and ultra-deep sequencing of serial samples from 16 patients.#leusm Full recap of findings: https://buff.ly/2Ryq33c pic.twitter.com/Qo4gLvPsDP
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
True or False? There is no benefit to continuing a full induction regimen until progression without a period of observation or maintenance therapy in patients with metastatic
#colorectal cancer.#crcsm Take the quiz: https://buff.ly/30VO1ZA pic.twitter.com/3DCR7K8gfT
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Loretta Nastoupil, MD,
@MDAndersonNews, discusses results from a study exploring obinutuzumab therapy plus lenalidomide in patients with untreated, high tumor burden FL.#lymphoma Watch here: https://buff.ly/36t50Dn pic.twitter.com/sCHL7uSd2H
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Researchers suggest that patients with muscle-invasive
#bladdercancer who are more likely to receive neoadjuvant versus adjuvant chemotherapy have increased overall survival. Read more: https://buff.ly/2GjMAdE pic.twitter.com/PDykGQXpfT
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Oncology Learning Network proslijedio/la je Tweet
If you enjoy the Lymphoma, Leukemia & Myeloma Congress: The same team behind this event also puts on
@GreatDebatesHem - a debate-style meeting with 3 locations in 2020: http://bit.ly/2yszKpW pic.twitter.com/8ipYLT81n5
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The
@US_FDA has approved tazemetostat for the treatment of patients with metastatic or locally advanced epithelioid sarcoma ineligible for complete resection. Read more: https://buff.ly/2RnyqhX pic.twitter.com/ATd7ndYXJd
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
In this panel discussion,
@DrAEvens,@DrJulieVose,@DrJFriedberg and Dr. Stephen Ansell share key updates on the use of brentuximab vedotin for the treatment of classical Hodgkin#lymphoma. Check out the 6-part series here: https://buff.ly/3ayOMMl#lymsm#ASH19pic.twitter.com/oM1VP3mInA
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
“Concurrent chemoradiotherapy administered with proton therapy might reduce toxicity and achieve comparable cancer control outcomes compared with conventional photon radiotherapy..."
#RadOnc Read more study findings from investigators@PennMedicine here: https://buff.ly/37dUn8M pic.twitter.com/og9zVyIf18
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Rimas Orentas, PhD,
@seattlechildren discusses CAR-T resistance in patients with B-ALL and results from an analysis presented at the 2019 ASH Annual Meeting.#ASH19#leusm Read this short interview here: https://buff.ly/36dS58k pic.twitter.com/kEGVkOGeqA
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Results from a study comparing outcomes of patients with
#follicular lymphoma or#CLL treated with idelalisib in clinical trials vs the clinical setting showed less favorable outcomes in the clinical setting.#lymsm Read more here: https://buff.ly/2tGuPCF pic.twitter.com/emyI1AvXCS
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.